| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for BioCurex Inc. > News item |
BioCurex returns to the OTC Bulletin Board; European single patent application denied
By E. Janene Geiss
Philadelphia, Aug. 23 - BioCurex Inc. announced Wednesday that following the filing of a form 2C11, the National Association of Securities Dealers has authorized the brokerage firm Lampost Capital LC to quote BioCurex shares on the Over-the-Counter Bulletin Board under the symbol "BOCX" effective immediately.
Company officials said this is not the last step in its interest to maximize its exposure to the advanced markets, according to a company news release. BioCurex officials said they will continue to seek global coverage of the company.
The company said it has received patents in the United States, Russia, China and Australia.
BioCurex said it submitted a single patent application to the European Patent Office with more than 40 claims rather than separate its diagnostic, imaging and therapeutic claims.
Recently, the approach has not succeeded with the European Patent Office where approval for the single patent application has been denied, although the company said it has not yet received an official response with the details from the patent office.
The company said its European attorneys believe gaining approval in a subsequent action is probable once the original claims are filed separately under different applications in a process called "separation in part."
In addition, the company said it is preparing to file one or more new patents covering inventions developed in the past few moths.
These inventions mainly relate to the Recaf blood tests and could extend the patent protection for another 17 to 20 years. These patents will not only be filed in Europe but also in the United States and other countries.
BioCurex is a Richmond, B.C., biotechnology company focused on cancer diagnosis, imaging and therapy.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.